查看文章

Background:  The percentage of diabetic patients who do not benefit from the protective effect of aspirin is larger than in other populations at cardiovascular risk.

Objective:  We compared the ability of aspirin to suppress TxA2 and platelet activation in vivo, in type‐2 diabetics vs. high‐risk non‐diabetic patients.

Methods:  Urinary 11‐dehydro‐TXB2, plasma sCD40 L, and sP‐selectin were measured, together with indices of low‐grade inflammation, glycemic control, and lipid profile, in 82 patients with type‐2 diabetes and 39 without diabetes, treated with low doses of aspirin.

Results:  Urinary 11‐dehydro‐TxB2, plasma sCD40L and sP‐selectin were significantly higher in diabetics than in controls: [38.9 (27.8–63.3) vs. 28.5 (22.5–43.9) ng mmol⁻¹ of creatinine, P = 0.02], [1.06 (0.42–3.06) vs. 0.35 (0.22–0.95) ng mL⁻¹; P = 0.0001], [37.0 (16.8–85.6) vs. 20.0 (11.2–35.6) ng mL⁻¹, P = 0.0001], respectively …